294 related articles for article (PubMed ID: 1316775)
41. Sensitive serum markers for detecting pancreatic cancer.
Hayakawa T; Kondo T; Shibata T; Hamano H; Kitagawa M; Sakai Y; Ono H
Cancer; 1988 May; 61(9):1827-31. PubMed ID: 2451556
[TBL] [Abstract][Full Text] [Related]
42. Tumour marker detection in oesophageal carcinoma.
Mealy K; Feely J; Reid I; McSweeney J; Walsh T; Hennessy TP
Eur J Surg Oncol; 1996 Oct; 22(5):505-7. PubMed ID: 8903494
[TBL] [Abstract][Full Text] [Related]
43. Carbohydrate antigen 19-9 (CA 19-9) and carcinoembryonic antigen (CEA) in pancreatic cancer. Role of age and liver dysfunction.
Del Favero G; Fabris C; Panucci A; Basso D; Plebani M; Baccaglini U; Leandro G; Burlina A; Naccarato R
Bull Cancer; 1986; 73(3):251-5. PubMed ID: 3530354
[TBL] [Abstract][Full Text] [Related]
44. Evaluation of serum pancreatic enzymes, carbohydrate antigen 19-9, and carcinoembryonic antigen in various pancreatic diseases.
Satake K; Kanazawa G; Kho I; Chung Y; Umeyama K
Am J Gastroenterol; 1985 Aug; 80(8):630-6. PubMed ID: 2411125
[TBL] [Abstract][Full Text] [Related]
45. Clinical values of CA19-9, CA125 and CEA in malignant obstructive jaundice.
Ng WW; Tong KJ; Tam TN; Lee SD
Zhonghua Yi Xue Za Zhi (Taipei); 1995 Jun; 55(6):438-46. PubMed ID: 7634181
[TBL] [Abstract][Full Text] [Related]
46. [Tumor markers for pancreatic and biliary tract cancer].
Takezako Y; Okusaka T; Ueno H; Ikeda M; Morizane C; Najima M
Gan To Kagaku Ryoho; 2004 Sep; 31(9):1443-6. PubMed ID: 15446574
[TBL] [Abstract][Full Text] [Related]
47. Diagnostic pitfall; interpretation of CA 19-9 concentrations in the presence of hepatic dysfunction.
Pearce S; Thornes H; Carr D; Tanner A
Gut; 1994 May; 35(5):707-8. PubMed ID: 8200572
[TBL] [Abstract][Full Text] [Related]
48. CEA, CA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice.
Duraker N; Hot S; Polat Y; Höbek A; Gençler N; Urhan N
J Surg Oncol; 2007 Feb; 95(2):142-7. PubMed ID: 17262731
[TBL] [Abstract][Full Text] [Related]
49. [Tumour markers of pancreatic cancer (tumour associated antigens)].
Groblewska M; Mroczko B; Szmitkowski M
Pol Arch Med Wewn; 2005 Jun; 113(6):585-93. PubMed ID: 16454450
[No Abstract] [Full Text] [Related]
50. A clinical evaluation of carbohydrate antigen 19-9 and carcinoembryonic antigen in patients with pancreatic carcinoma.
Satake K; Kanazawa G; Kho I; Chung YS; Umeyama K
J Surg Oncol; 1985 May; 29(1):15-21. PubMed ID: 3857396
[TBL] [Abstract][Full Text] [Related]
51. Comparative study of carbohydrate antigen 195 and carcinoembryonic antigen for the diagnosis of pancreatic carcinoma.
Andicoechea A; Vizoso F; Alexandre E; Martínez A; Cruz Díez M; Riera L; Martinez E; Ruibal A
World J Surg; 1999 Mar; 23(3):227-31; discussion 231-2. PubMed ID: 9933690
[TBL] [Abstract][Full Text] [Related]
52. Bile levels of carcino-embryonic antigen in patients with hepatopancreatobiliary disease.
Buffet C; Fourré C; Altman C; Prat F; Fritsch J; Choury A; Briantais MJ; Desgrez A; Etienne JP
Eur J Gastroenterol Hepatol; 1996 Feb; 8(2):131-4. PubMed ID: 8723416
[TBL] [Abstract][Full Text] [Related]
53. CA 72-4 compared with CEA and CA 19-9 as a marker of some gastrointestinal malignancies.
Lopez JB; Royan GP; Lakhwani MN; Mahadaven M; Timor J
Int J Biol Markers; 1999; 14(3):172-7. PubMed ID: 10569140
[TBL] [Abstract][Full Text] [Related]
54. Measurement of serum carcinoembryonic antigen, carbohydrate antigen 19-9, cytokeratin-19 fragment and matrix metalloproteinase-7 for detecting cholangiocarcinoma: a preliminary case-control study.
Lumachi F; Lo Re G; Tozzoli R; D'Aurizio F; Facomer F; Chiara GB; Basso SM
Anticancer Res; 2014 Nov; 34(11):6663-7. PubMed ID: 25368272
[TBL] [Abstract][Full Text] [Related]
55. Multiparametric tumor marker (CA 19-9, CEA, AFP, POA) analyses of pancreatic juices and sera in pancreatic diseases.
Schmiegel WH; Eberl W; Kreiker C; Kalthoff H; Bützow GH; Jessen K; Klapdor R; Soehendra N; Wargenau M; Classen M
Hepatogastroenterology; 1985 Jun; 32(3):141-5. PubMed ID: 2410346
[TBL] [Abstract][Full Text] [Related]
56. Comparative effectiveness of the tumour diagnostics, CA 19-9, CA 125 and carcinoembryonic antigen in patients with diseases of the digestive system.
Sakamoto K; Haga Y; Yoshimura R; Egami H; Yokoyama Y; Akagi M
Gut; 1987 Mar; 28(3):323-9. PubMed ID: 3471687
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer.
Haglund C; Roberts PJ; Kuusela P; Scheinin TM; Mäkelä O; Jalanko H
Br J Cancer; 1986 Feb; 53(2):197-202. PubMed ID: 3456787
[TBL] [Abstract][Full Text] [Related]
58. [Role of carcinoembryonic antigen, carbohydrate antigen 19-9 and cytology of bile in diagnosis of biliary and pancreatic cancer].
Matsuda M; Shimizu Y; Chikamatsu E; Takayanagi K; Ishigure H; Murakami S; Odani K
Nihon Geka Gakkai Zasshi; 1991 Jun; 92(6):716-21. PubMed ID: 1886576
[TBL] [Abstract][Full Text] [Related]
59. Various tumor markers for small pancreatic cancer with special reference to the present status of pancreatic cancer in Japan and our experience over the past 2 years.
Satake K; Chung YS; Yokomatsu H; Nakata B; Sawada T; Nishiwaki H; Umeyama K
Pancreas; 1991 Mar; 6(2):234-41. PubMed ID: 1886892
[TBL] [Abstract][Full Text] [Related]
60. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
